ProCE Banner Activity

ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

Podcast Episodes

Audio podcast with key clinical highlights for gynecologic cancers from the 2024 ESMO congress. Listen to experts put new trial results into context and share their perspectives and takeaway points for integrating new data into your everyday practice. 

Released: October 02, 2024

Expiration: October 01, 2025

Share

Faculty

Alexandra Leary

Alexandra Leary, MD, PhD

Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab
Institut Gustave Roussy
Paris, France

Ana Oaknin

Ana Oaknin, MD, PhD

Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Merck Sharp & Dohme LLC, and Seagen Inc.

AstraZeneca

Merck Sharp & Dohme, LLC

Seagen Inc.

Disclosure

Primary Author

Alexandra Leary, MD, PhD

Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab
Institut Gustave Roussy
Paris, France

Alexandra Leary, MD, PhD: consultant/advisor/speaker: AbbVie, Apmonia, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Merck Sharp & Dohme, Zentalis.

Ana Oaknin, MD, PhD

Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Ana Oaknin, MD, PhD: consultant/advisor/speaker: AbbVie, Agenus, AstraZeneca, Clovis, Corcept Therapeutics, Daiichi Sankyo, Debiopharm International, Deciphera, Eisai, Exelisis, F. Hoffmann-La Roche, Genmab, GlaxoSmithKline, ImmunoGen, Itheos, Merck Sharp & Dohme, Mersana Therapeutics, Myriad Genetics, NovoCure, OneXerna, PharmaMar, Regeneron, Sattucklabs, Seagen/Pfizer, Sutro Biopharma, TORL Therapeutics, Zentalis, Zymeworks; other financial or material support: AstraZeneca, PharmaMar, Roche.